Aridis Pharmaceuticals
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
983 University Ave Bldg B, Los Gatos, Ca...Phone Number
(408) 385-1742Website
www.aridispharma.comRevenue
$22.4 MillionStock Symbol
ARDSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.Explore more
Aridis Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aridis Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Aridis Pharmaceuticals has new funding data
Check if Aridis Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Aridis Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Aridis Pharmaceuticals recently announced quarterly report
Check out if Aridis Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Aridis Pharmaceuticals launches new products
Aridis Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Aridis Pharmaceuticals
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Aridis Pharmaceuticals
Compare insights from companies similar to Aridis Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aridis Pharmaceuticals
$22.4M
11-50
Public
$6.8M
2003
YW
Yvonne WalkerAssociate Director, Clinical Operations
Company Profile Activity
Activity Insights
Aridis Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aridis Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aridis Pharmaceuticals.
Aridis Pharmaceuticals financials insights
Gather financial insights about Aridis Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$3.5M
2015
Debt
$3M
2020
Debt
$350K
Aridis Pharmaceuticals Tech Stack
A closer look at the technologies used by Aridis Pharmaceuticals
Most Recent Scoops
Project
, according to a high-level source in marketing, is planning to leverage AI-driven data enrichment and hygiene over the next six to twelve months.
Artificial Intelligence
Executive Move
Board of Directors
Earnings
Aridis Pharmaceuticals has reported revenues of $1.19 million for Q1 2022, missing expectations of $2.00 million.
Earnings
Open Position
Open Position
Aridis Pharmaceuticals News & Media
Aridis Provides Corporate Update
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments.Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that its 2023 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum. The Annual Meeting has been adjoAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of HealthAridis Pharmaceuticals Announces $2 Million Offering
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the pricing of an offering of 10,000,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aridis Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the tr... Read More
